Brolucizumab Versus Aflibercept on Visual and Anatomical Outcomes in Diabetic Macular Edema
Status:
COMPLETED
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
This retrospective, comparative cohort study included 38 eyes from 38 patients with center-involving diabetic macular edema (DME), treated at Benha University Hospital. Patients were divided into two groups: 19 eyes received intravitreal Brolucizumab (6 mg), and 19 eyes received intravitreal Aflibercept (2 mg), with the aim of comparing their efficacy and safety over a 6-month period.